PHATHOM PHARMACEUTICALS INC (PHAT) Stock News

USA - Nasdaq - NASDAQ:PHAT - US71722W1071 - Common Stock

15 USD

+0.64 (+4.46%)

Last: 11/21/2025, 8:00:01 PM

14.41 USD

-0.59 (-3.93%)

After Hours: 11/21/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PHAT Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill

News Image

High Growth Momentum and Technical Strength Drive PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT)

20 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

21 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

21 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

25 days ago - By: Benzinga - Mentions: IR CDP ENTG BUD ...

Earnings Scheduled For October 30, 2025

25 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

25 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

2 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

2 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

2 months ago - By: Bloomberg - Mentions: LLY BMY ABBV BBIO

FDA Letters Flag Oprah Video, Morgan Freeman Ad in Crackdown

3 months ago - By: Zacks Investment Research

Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

4 months ago - By: The Motley Fool

Phathom (PHAT) Q2 Revenue Jumps 441%

4 months ago - By: Zacks Investment Research - Mentions: BOLT

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

4 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

4 months ago - By: Zacks Investment Research - Mentions: MNKD

MannKind (MNKD) Reports Break-Even Earnings for Q2

4 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

4 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

5 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Phathom Pharmaceuticals - Mentions: SAGE

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

5 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032